Insulet announces Omnipod 5 Automated Insulin Delivery System available in U.K.

Insulet Corporation announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older with type 1 diabetes in the United Kingdom. “Since its commercial launch in the United States, Omnipod 5 has had a remarkable impact on people with diabetes,” said Jim Hollingshead, Insulet President and CEO. “Every day, we hear how this revolutionary experience of Omnipod 5 reduces the burden and improves quality of life for people with diabetes, and we are excited to make a difference in other parts of the world, beginning with the UK. We are committed to making Omnipod 5 an option for as many people as possible, as quickly as we can, and working hard to secure broad access globally.” The Omnipod 5 System is where simplicity meets advanced technology. Omnipod 5 is the first CE marked tubeless hybrid closed loop system that integrates with the Dexcom G6 Continuous Glucose Monitoring System to automatically adjust insulin delivery and help protect against high and low glucose levels. The system consists of the tubeless Pod enhanced with SmartAdjust technology and the Omnipod 5 Controller with its integrated SmartBolus Calculator. The system is interoperable with the Dexcom G6 CGM for automated insulin delivery.